MoonLake Immunotherapeutics Banner Image

MoonLake Immunotherapeutics

  • Ticker MLTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
MoonLake Immunotherapeutics Logo Image
  • 11-50 Employees
  • Based in Zug, Switzerland
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company’s focus is on inflammatoryMore diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics

Most Recent Annual Report

MoonLake Immunotherapeutics
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

MoonLake Immunotherapeutics Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!